Compare RCMT & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCMT | BNR |
|---|---|---|
| Founded | 1971 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 196.0M | 179.7M |
| IPO Year | 1997 | 2019 |
| Metric | RCMT | BNR |
|---|---|---|
| Price | $23.84 | $9.05 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $36.00 | N/A |
| AVG Volume (30 Days) | ★ 79.4K | 14.5K |
| Earning Date | 04-03-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.38 | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $186,737,000.00 | N/A |
| Revenue This Year | $11.89 | $111.65 |
| Revenue Next Year | $12.46 | N/A |
| P/E Ratio | $45.92 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $17.26 | $2.95 |
| 52 Week High | $32.50 | $41.72 |
| Indicator | RCMT | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 44.56 | 26.83 |
| Support Level | $21.11 | $7.99 |
| Resistance Level | $24.56 | $9.70 |
| Average True Range (ATR) | 1.01 | 1.19 |
| MACD | 0.14 | -0.50 |
| Stochastic Oscillator | 87.72 | 6.87 |
RCM Technologies Inc is a provider of business and technology solutions designed to enhance and maximize the operational performance of its customers. It operates in three segments: Specialty Health Care, Engineering, and Life Sciences, Data and Solutions (LS&D). The company generates maximum revenue from the Specialty Health Care segment that provides staffing solutions including medical healthcare professionals, health information management professionals, nurses, paraprofessionals, physicians, and therapists. Geographically, it derives a majority of its revenue from the United States and also has a presence in Canada, Puerto Rico, the Philippines, and Europe.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.